Rutin

Summary

Rutin (CHEMBL226335) is an approved small-molecule antioxidant (ATC C05CA01); indicated across 3 conditions including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C05CA01 (+1 more)
• Indications: 3 conditions
• Clinical trials: 7
• Chemistry: 610.5 Da · C27H30O16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL226335
Name	Rutin
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	5280805
ChEBI	CHEBI:28527
ATC	C05CA01, C05CA51
Molecular formula	C27H30O16
Molecular weight	610.5
InChIKey	IKGXIBQEEMLURG-NVPNHPEKSA-N

SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O

IUPAC name: 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one

ChEBI definition: A rutinoside that is quercetin with the hydroxy group at position C-3 substituted with glucose and rhamnose sugar groups.

Pharmacological roles (ChEBI): antioxidant.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: Birutan, C.I. 75730, Globulariacitrin, Ilixanthin, Myrticolorin, Novarrutina, NSC-9220, Osyritrin, Paliuroside, Rutin, Rutoside, Rutosido

Parent form; salt/anhydrous children: CHEMBL455260, CHEMBL1883743

Patent coverage: 31,110 distinct patent families (57,988 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 57,636 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 23 (assay-derived). Sample: Neuromedin-U receptor 2, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Xanthine dehydrogenase/oxidase, Amine oxidase [flavin-containing] A, Trypsin, Acetylcholinesterase.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 25 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BACE1	8.42	IC50	3.8	nM	CHEMBL_ACT_25030897
ACHE	7.92	IC50	12	nM	CHEMBL_ACT_12592949
HMGB1	6.58	Kd	260	nM	CHEMBL_ACT_29087337
NMUR2	5.92	EC50	1200	nM	CHEMBL_ACT_15087081
KDM1A	5.67	IC50	2160	nM	CHEMBL_ACT_18878402
GAA	5.5	Potency	3162	nM	CHEMBL_ACT_4937999
MAOA	5.41	IC50	3890	nM	CHEMBL_ACT_25040059
MAPK1	5.1	Potency	7943	nM	CHEMBL_ACT_4713468
POLB	5.05	Potency	8912	nM	CHEMBL_ACT_4889709
ADRA2A	5.03	Ki	9340	nM	CHEMBL_ACT_3285825
ADRA2C	5.02	Ki	9637	nM	CHEMBL_ACT_3285824

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	2	MONDO:0004995	EFO:0000319

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
Not specified	5
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07310407	PHASE2	NOT_YET_RECRUITING	Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
NCT06916494	PHASE1	RECRUITING	Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
NCT06718452	Not specified	NOT_YET_RECRUITING	Tinnitus and Treatment With umPEA-LUT
NCT07564999	Not specified	ENROLLING_BY_INVITATION	The Effect of a Peer-Based Instructional Disaster Education Program on Disaster Preparedness Beliefs and Disaster Attitudes of First Aid and Emergency Program Students
NCT00003365	Not specified	TERMINATED	Sulindac and Plant Compounds in Preventing Colon Cancer
NCT06298383	Not specified	COMPLETED	The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain
NCT07147842	Not specified	COMPLETED	Rutin Therapy Role in Reducing Ulcerative Colitis Severity

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).